At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating Gantenerumab, Solanezumab, and 2 other interventions for Alzheimers Disease and 2 related conditions. Completed, enrolled 194 participants across 25 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers. This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005
Study Details
Timeline
Interventions
Subcutaneously every 4 weeks at escalating doses
Intravenous infusion every 4 weeks at escalating doses
Subcutaneous injection of placebo every 4 weeks
Intravenous infusion of placebo every 4 weeks